1. Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
- Author
-
Alireza Sahebi Shahem-abadi, Jaleel A. Miyan, Silke Haerteis, Sareh Pandamooz, Carl-Philipp Meinung, Afshin Borhani-Haghighi, Benjamin Jurek, Mehdi Dianatpour, James A. Downing, Zahra Baharvand, and Mohammad Saied Salehi
- Subjects
Pharmacology ,RM ,Protective immunity ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Transmission (medicine) ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,virus diseases ,Models, Theoretical ,Toxicology ,medicine.disease_cause ,Bioinformatics ,Antiviral Agents ,Pathogenesis ,Global health ,Humans ,Medicine ,business ,Pandemics ,Cellular Tropism ,Coronavirus - Abstract
In December 2019, a novel coronavirus crossed species barriers to infect humans and was effectively transmitted from person to person, leading including vaccines and antiviral drugs that could prevent or limit the burden or transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health priority. It is thus of utmost importance to assess possible therapeutic strategies against SARS-CoV-2 using experimental models that recapitulate aspects of the human disease. Here, we review available models currently being developed and used to study SARS-CoV-2 infection and highlight their application to screen potential therapeutic approaches, including repurposed antiviral drugs and vaccines. Each identified model provides a valuable insight into SARS-CoV-2 cellular tropism, replication kinetics, and cell damage that could ultimately enhance understanding of SARS-CoV-2 pathogenesis and protective immunity. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 62 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
- Published
- 2022
- Full Text
- View/download PDF